5 results on '"Dennis P.M. Hughes"'
Search Results
2. UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors
- Author
-
Brandon S. Brown, Shana L. Palla, Andrew J. Bean, Dennis P.M. Hughes, Yin Liu, Monica Gireud, Kristen Richards, Natalie Sirisaengtaksin, and Peter E. Zage
- Subjects
Cancer Research ,Cetuximab ,biology ,Cell growth ,business.industry ,Cancer ,medicine.disease ,Oncology ,Growth factor receptor ,Neuroblastoma ,medicine ,Cancer research ,biology.protein ,Epidermal growth factor receptor ,business ,neoplasms ,Tyrosine kinase ,medicine.drug ,EGFR inhibitors - Abstract
BACKGROUND: The UBE4B gene, which is located on chromosome 1p36, encodes a ubiquitin ligase that interacts with hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs), a protein involved in epidermal growth factor receptor (EGFR) trafficking, suggesting a link between EGFR trafficking and neuroblastoma pathogenesis. The authors analyzed the roles of UBE4B in the outcomes of patients with neuroblastoma and in neuroblastoma tumor cell proliferation, EGFR trafficking, and response to EGFR inhibition. METHODS: The association between UBE4B expression and the survival of patients with neuroblastoma was examined using available microarray data sets. UBE4B and EGFR protein levels were measured in patient tumor samples, EGFR degradation rates were measured in neuroblastoma cell lines, and the effects of UBE4B on neuroblastoma tumor cell growth were analyzed. The effects of the EGFR inhibitor cetuximab were examined in neuroblastoma cells that expressed wild-type and mutant UBE4B. RESULTS: Low UBE4B gene expression is associated with poor outcomes in patients with neuroblastoma. UBE4B overexpression reduced neuroblastoma tumor cell proliferation, and UBE4B expression was inversely related to EGFR expression in tumor samples. EGFR degradation rates correlated with cellular UBE4B levels. Enhanced expression of catalytically active UBE4B resulted in reduced sensitivity to EGFR inhibition. CONCLUSIONS: The current study demonstrates associations between UBE4B expression and the outcomes of patients with neuroblastoma and between UBE4B and EGFR expression in neuroblastoma tumor samples. Moreover, levels of UBE4B influence neuroblastoma tumor cell proliferation, EGFR degradation, and response to EGFR inhibition. These results suggest UBE4B-mediated growth factor receptor trafficking may contribute to the poor prognosis of patients who have neuroblastoma tumors with 1p36 deletions and that UBE4B expression may be a marker that can predict responses of neuroblastoma tumors to treatment. Cancer 2013. © 2012 American Cancer Society.
- Published
- 2012
3. Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo
- Author
-
Dennis P.M. Hughes, Nadine Van Roy, Patrick A. Zweidler-McKay, Jesus Trevino, Frank Speleman, Peter E. Zage, and Kristen Richards
- Subjects
Cancer Research ,Morpholines ,Apoptosis ,Biology ,Article ,Receptor tyrosine kinase ,Erlotinib Hydrochloride ,Mice ,Neuroblastoma ,chemistry.chemical_compound ,ErbB ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Epidermal growth factor receptor ,Protein Kinase Inhibitors ,neoplasms ,Cell Proliferation ,Mice, Knockout ,medicine.disease ,Pediatric cancer ,ErbB Receptors ,Oncology ,chemistry ,Quinazolines ,Cancer research ,biology.protein ,Erlotinib ,Growth inhibition ,Neoplasm Transplantation ,Signal Transduction ,medicine.drug - Abstract
BACKGROUND: ERBB receptor tyrosine kinases can mediate proliferation, migration, adhesion, differentiation, and survival in many types of cells and play critical roles in many malignancies. Recent reports suggest a role for EGFR signaling in proliferation and survival of neuroblastoma, a common form of pediatric cancer that often has an extremely poor outcome. METHODS: The authors examined ERBB family expression in neuroblastoma cell lines and patient samples by flow cytometry, western blot, and quantitative real time polymerase chain reaction (Q-PCR). Response to ERBB inhibition was assessed in vitro by cell-cycle analysis and western blot and in vivo by serial tumor-size measurements. RESULTS: A panel of neuroblastoma cell lines and primary patient tumors expressed EGFR, HER-3, and HER-4, with HER-2 in some tumors. HER-4 mRNA was expressed predominantly in cleavable isoforms. Whereas EGFR inhibition with erlotinib and pan-ERBB inhibition with CI-1033 inhibited EGF-induced phosphorylation of EGFR, AKT, and ERK1/2, only CI-1033 induced growth inhibition and dose-dependent apoptosis in vitro. Both CI-1033 and erlotinib treatment of neuroblastoma xenograft tumors resulted in decreased tumor growth in vivo, although CI-1033 was more effective. In vivo expression of EGFR was observed predominantly in vascular endothelial cells. CONCLUSIONS: Pan-ERBB inhibition is required for ERBB-related neuroblastoma apoptosis in vitro, although EGFR contributes indirectly to tumor growth in vivo. Inhibition of EGFR in endothelial cells may be an important aspect of erlotinib's impact on neuroblastoma growth in vivo. Our results suggest that non-EGFR ERBB family members contribute directly to neuroblastoma growth and survival, and pan-ERBB inhibition represents a potential therapeutic target for treating neuroblastoma. Cancer 2010. © 2010 American Cancer Society.
- Published
- 2010
4. Multimodality treatment of osteosarcoma: Radiation in a high-risk cohort
- Author
-
Christopher E. Pelloski, Cynthia E. Herzog, Pete Anderson, Winston W. Huh, Anita Mahajan, Eric L. Chang, Shiao Y. Woo, Dennis P.M. Hughes, and David G. Kornguth
- Subjects
Adult ,Male ,Adolescent ,medicine.medical_treatment ,Bone Neoplasms ,Multimodality Therapy ,Medical Records ,Metastasis ,Cohort Studies ,Risk Factors ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Ifosfamide ,Child ,Survival rate ,Etoposide ,Retrospective Studies ,Osteosarcoma ,Chemotherapy ,business.industry ,Radiotherapy Dosage ,Hematology ,medicine.disease ,Combined Modality Therapy ,Survival Rate ,Radiation therapy ,Methotrexate ,Unresectable Osteosarcoma ,Oncology ,Doxorubicin ,Pediatrics, Perinatology and Child Health ,Female ,Cisplatin ,Neoplasm Recurrence, Local ,business ,Nuclear medicine ,Follow-Up Studies ,medicine.drug - Abstract
Purpose Chemotherapy during radiation and/or bone-seeking radioisotope therapy (153-samarium; 1 mCi/kg) during radiation may improve osteosarcoma cancer control. Patients and Methods We analyzed our preliminary radiation experience in high-risk, metastatic, and/or recurrent patients during a consecutive period of 20 months (May 2005–December 2006). Results Thirty-nine high-risk osteosarcoma patients had radiotherapy; 119 sites were irradiated. A median four sites were irradiated per patient (range 1–14). The median radiation dose and number of fractions of radiation was 30 Gy in 10 fractions (range 10–70 Gy in 4–35 fractions). Chemotherapy, most commonly ifosfamide or methotrexate, was used in 80% (100/119) radiotherapy courses. Of 38 painful sites, 29 had improvement (76%), 4 had no change (10%), and 5 had more pain (13%). Objective and potentially durable responses were documented using PET-CT and bone scans with persistent and sustained reduction of standard uptake values (SUVs; initial SUV of indication lesion 9.5 became
- Published
- 2008
5. Erratum
- Author
-
Bruce Blumberg, Dennis P.M. Hughes, Michelle M. Tabb, Laurence H. Baker, Thomas J. Giordano, James M. Rae, Dafydd G. Thomas, Michelle L. Lizyness, Paul F. Hollenberg, and Jose M. Larios
- Subjects
Cancer Research ,Pregnane X receptor ,Oncology ,Cell culture ,business.industry ,Cancer research ,medicine ,Cancer ,Osteosarcoma ,Drug resistance ,Pharmacology ,medicine.disease ,business - Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.